P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's diseaseB. Feagan, B E Sands, C.F. Chiou et al.|Journal of Crohn s and Colitis|2012Cited by 9
Unseen space weather also relates to cardiac eventsGermaine Cornélissen, М. Д. Митиш, F Halberg et al.|Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)|2008Cited by 4
OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1P. Rutgeerts, WJ Sandborn, Christopher Gasink et al.|Gut|2016Cited by 4